Pro-Pharmaceuticals Starts Dosing in Cancer Trial
Posted on: Wednesday, 28 February 2007, 12:01 CST
Pro-Pharmaceuticals has started third site dosing in a phase II colorectal cancer trial with Davanat, a cancer drug that has the potential to reduce toxicity.
The phase II trial will examine Davanat with Avastin, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced, unresectable or metastatic colorectal cancer and unable to tolerate intensive chemotherapy with an endpoint of tumor shrinkage.
Davanat targets specific lectin receptors (Galectins) that are over-expressed on cancer cells. According to the company, this form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.
"When we combine the results from this front line trial, with the positive results from our phase I/II trials of end stage cancer patients, we believe it will prove the efficacy enhancing affect and toxicity reduction of Davanat when co-administered with chemotherapeutics and biologics to treat cancer," said Tomasz Zastawny, director Clinical Trials, Pro-Pharmaceuticals.
Additionally, the company is actively recruiting and dosing patients in a phase II study of Davanat with 5-FU for first line treatment of advanced biliary cancer.
The primary objectives of the trial are a partial or complete tumor response and stable disease. Secondary outcomes include progression-free survival and quality of life. A cholangiocarcinoma patient from the phase I trial remained on study for 13 months, far exceeding expectations.
Source: Datamonitor
Related Articles
- Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
- ImClone Initiates Enrollment for Phase I/II Pancreatic Cancer Trials
- Introgen's Advexin Found Effective in Phase II Cancer Trial
- Celsion Gets FDA Nod for Phase III Liver Cancer Trial
- CELSION Secures Special Protocol Assessment of Its Pivotal Phase III Liver Cancer Trial From FDA
- Results of RTA 402 Phase I Cancer Trial Presented at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
- Sunesis Pharmaceuticals Reports Positive Initial Results From Phase 2 Small Cell Lung Cancer Trial With SNS-595
- ZIOPHARM Announces Interim Results in ZIO-101 Phase I Solid Tumor Cancer Trial; Clinical Activity in Several Cancers
- Pro-Pharmaceuticals Retains Dr. James T. Gourzis to Provide Clinical Management & Strategic Development of Its Europe-Based Phase III Colorectal Cancer Trial
- Antigenics Updates Business Strategy and Outlines Timeline for the Analysis of Its Phase 3 Kidney Cancer Trial
 |
 |
User Comments (0)
RSS Feeds